Should you buy Alnylam Pharmaceuticals (ALNY)?
Updated
Alnylam combines an unusually strong quality profile — wide economic moat, Rule of 40 score of 101, 96% year-over-year revenue growth, and a Piotroski financial health score of 8 out of 9 — with a forward earnings multiple that remains undemanding for growth of this caliber at a PEG of 0.49; the principal near-term obstacle is a confirmed technical downtrend that, until resolved, limits the initial position size for all but the most patient investors.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Revenue grew 96% year-over-year, the combined growth-and-profitability Rule of 40 score is 101, the business carries a wide economic moat, and the financial health screen scores 8 of 9 — yet the forward earnings multiple sits at a PEG of 0.49, an unusually low price to pay for a franchise with these characteristics. Quality breakdown | Revenue growth sustains above 50% year-over-year and the Rule of 40 remains above 80 over the next 12 months, validating the quality-growth combination at current prices. | →Stable |
| CounterBiotechs with triple-digit revenue growth rates almost always face deceleration as the base effect compounds; the current valuation implicitly assumes prolonged exceptional growth, and any meaningful slowdown would compress the multiple sharply. | ||
The stock is trading below its 200-day moving average with the trend slope declining at 4.1% over 30 days, on-balance volume is falling, and a death cross has triggered — conditions that have historically been poor entry points even for high-quality businesses until the technical backdrop stabilizes. Momentum breakdown | Price reclaims the 200-day moving average and on-balance volume turns positive, signaling that the supply overhang has cleared. | →Stable |
| CounterTechnical price action in high-quality businesses with strong fundamental momentum can diverge from fundamentals for extended periods before mean-reverting sharply; a patient investor who waits for technical confirmation may miss the bulk of the initial recovery move. | ||
The company carries a debt-to-equity ratio of 2.8, which at current growth rates is manageable but leaves less financial cushion if revenue momentum softens — elevated leverage can accelerate downside scenarios in a way that unlevered peers would not experience. Bear case | Debt-to-equity ratio declines below 2.0 over the next four quarters as cash generation from commercial products pays down obligations. | →Stable |
| CounterA high-growth business with a wide economic moat and strong free-cash-flow trajectory can comfortably service elevated debt; leverage used to fund product expansion may be value-accretive if the underlying assets continue to generate returns above the cost of capital. | ||
Revenue grew 96% year-over-year, the combined growth-and-profitability Rule of 40 score is 101, the business carries a wide economic moat, and the financial health screen scores 8 of 9 — yet the forward earnings multiple sits at a PEG of 0.49, an unusually low price to pay for a franchise with these characteristics.
→Stable- Expectation
- Revenue growth sustains above 50% year-over-year and the Rule of 40 remains above 80 over the next 12 months, validating the quality-growth combination at current prices.
CounterBiotechs with triple-digit revenue growth rates almost always face deceleration as the base effect compounds; the current valuation implicitly assumes prolonged exceptional growth, and any meaningful slowdown would compress the multiple sharply.
The stock is trading below its 200-day moving average with the trend slope declining at 4.1% over 30 days, on-balance volume is falling, and a death cross has triggered — conditions that have historically been poor entry points even for high-quality businesses until the technical backdrop stabilizes.
→Stable- Expectation
- Price reclaims the 200-day moving average and on-balance volume turns positive, signaling that the supply overhang has cleared.
CounterTechnical price action in high-quality businesses with strong fundamental momentum can diverge from fundamentals for extended periods before mean-reverting sharply; a patient investor who waits for technical confirmation may miss the bulk of the initial recovery move.
The company carries a debt-to-equity ratio of 2.8, which at current growth rates is manageable but leaves less financial cushion if revenue momentum softens — elevated leverage can accelerate downside scenarios in a way that unlevered peers would not experience.
→Stable- Expectation
- Debt-to-equity ratio declines below 2.0 over the next four quarters as cash generation from commercial products pays down obligations.
CounterA high-growth business with a wide economic moat and strong free-cash-flow trajectory can comfortably service elevated debt; leverage used to fund product expansion may be value-accretive if the underlying assets continue to generate returns above the cost of capital.
▸ Show 1 more pillar▾ Show fewer
Three of the last four quarters produced positive earnings surprises, with the three beats averaging a 74% upside to estimates; the single miss occurred in the second-most-recent quarter, and the most recent quarter returned to a 35% beat, suggesting the underlying earnings trajectory remains constructive.
→Stable- Expectation
- The earnings beat streak extends to four consecutive quarters without interruption over the next 12 months.
CounterThe average surprise figure is significantly inflated by a 120% beat in the oldest quarter of the window, which may reflect a one-time estimate reset rather than durable guidance discipline; if consensus estimates are now better calibrated, future surprises could narrow materially.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Revenue grew 96% year-over-year, the combined growth-and-profitability Rule of 40 score is 101, the business carries a wide economic moat, and the financial health screen scores 8 of 9 — yet the forward earnings multiple sits at a PEG of 0.49, an unusually low price to pay for a franchise with these characteristics.
Trip ifRevenue growth decelerates below 30% year-over-year for 2 consecutive quarters.
- P2The stock is trading below its 200-day moving average with the trend slope declining at 4.1% over 30 days, on-balance volume is falling, and a death cross has triggered — conditions that have historically been poor entry points even for high-quality businesses until the technical backdrop stabilizes.
Trip ifPrice closes above the 200-day moving average and on-balance volume turns positive for 20 or more consecutive sessions.
- P3The company carries a debt-to-equity ratio of 2.8, which at current growth rates is manageable but leaves less financial cushion if revenue momentum softens — elevated leverage can accelerate downside scenarios in a way that unlevered peers would not experience.
Trip ifDebt-to-equity ratio falls below 1.5 within 4 consecutive quarters.
- P4Three of the last four quarters produced positive earnings surprises, with the three beats averaging a 74% upside to estimates; the single miss occurred in the second-most-recent quarter, and the most recent quarter returned to a 35% beat, suggesting the underlying earnings trajectory remains constructive.
Trip ifEPS surprise falls below 0% in 2 of the next 3 reported quarters.
How the engine reached this verdict
TrendMatrix's engine output for Alnylam Pharmaceuticals, Inc. (ALNY) is STRONG_BUY_NOW with medium conviction, score 6.8/10 at $293.00. The C-path quality+growth combination cleared its gates — quality 8.1 and growth 10.0 — with 4.66 asymmetric R:R supporting the read.
The engine's suggested entry is $294.06 (current $293.00), target $392.69 (+34%), stop $273.48. Asymmetric reward-to-risk is 4.79. The engine's sizing output: 2.4% of portfolio at this asymmetry level (high-conviction tier).
On the bull side: Strong earnings beat streak (3/4); Positive news sentiment (+0.67); High-quality business. On the bear side: Leverage penalty (D/E 2.8): -1.5; Below 200-MA, MA slope -5.1%/30d (confirmed downtrend).
The closest gate to its boundary is death cross (quality=8.1>=7.5+momentum=6.4>=5.0 exempted). A flip to BUY_WAIT requires either a gate slipping below its threshold or asymmetry R:R compressing below 2.0.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates ALNY — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (3/4)
- ▸Positive news sentiment (+0.67)
- ▸High-quality business
Bear case
- ▸Leverage penalty (D/E 2.8): -1.5
- ▸Below 200-MA, MA slope -5.1%/30d (confirmed downtrend)